Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday November 2, 2009

DrStockPick.com Stock Report!

PWRM, AMLN

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday November 2nd, 2009, are:

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AMLN’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Saturday October 31, 2009

DrStockPick.com Stock Report!

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AMLN’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMLN, PWRM, MMM, CSRH, MYL, CVAT, STEM, AQNM

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

AMLN will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin’s president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a

...

Yesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon Limited for the development, commercialization and manufacture of a novel peptide therapeutic for the potential treatment of diabetes. This agreement should ensure the optimum utilization of the synergistic capabilities of both the companies. Both companies have a strong focus on the development of treatments for diabetes. While Amylin's "phybrid" technology will be used for the development of the candidate, Biocon will use its know-how in recombinant microbial expression to manufacture the compound. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. As per the terms of the agreement, development costs will be shared by the companies. Other details were not provided. The identification of a peptide therapeutic should help Amylin expand its diabetes product ...

On July 20, 2009, Amylin Pharmaceuticals Inc., (AMLN), Eli Lilly and Company (LLY) and Alkermes Inc. (ALKS) announced that their co-developed drug for type II diabetes, Exenatide once weekly was more effective in reducing average blood sugar over three months compared to Sanofi-Aventis' (SNY) Lantus (insulin glargine) on the basis of a 26-week open-label, clinical study in 467 patients with type II diabetes. Exenatide once weekly treatment also resulted in a mean weight loss of 5.8 pounds at 26 weeks, compared to a mean weight gain of 3.1 pounds for the Sanofi drug. This is again a desirable result as obesity is one of the primary causes of type II diabetes. Further, there were fewer cases of confirmed hypoglycemia (over-reduction in blood sugar) in patients treated with Exenatide once weekly compared to Lantus.  More than 23 million people in the U.S. are affected by diabetes, ...

Positive Results on LAR from DURATION-3 Study Yesterday, Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS) announced positive results on exenatide once weekly long acting release (LAR) formulation from a phase III head-to-head study which compared LAR with Sanofi-Aventis’ (SNY) Lantus (insulin glargine). The 26 week study was conducted in type II diabetes patients (n=467) who were unable to achieve adequate glucose control on metformin therapy alone or in combination with a sulfonylurea. Results showed that LAR was more effective in reducing blood sugar levels compared to Lantus (6.8% vs. 7%). Moreover, patients on LAR therapy achieved a mean weight loss of 5.8 pounds compared with a mean weight gain of 3.1 pounds in patients treated with Lantus. This is important as data indicate that weight loss helps patients in their efforts to achieve and sustain glycemic ...

NDA acceptance not enough for Alkermes On July 7, 2009, Alkermes, Inc. (ALKS), Eli Lilly (LLY) and Amylin Pharmaceuticals, Inc. (ALNY) announced the acceptance of the New Drug Application (NDA) for once-a-week diabetes drug Exenatide by the U.S. Food and Drug Administration (FDA). Exenatide once weekly is being co-developed by the three companies for type II diabetes. The application was filed by Alkermes in May 2009. Exenatide is an active ingredient of Byetta injection. It is presently available in the U.S. and in many countries across the globe as a treatment for type II diabetes patients who fail to achieve good glycemic control with commonly available oral therapies. Byetta is injected twice a day as against the once a week administration of the proposed drug. If approved, Exenatide once weekly would be the first and only once-a-week therapy for the treatment of ...

I've been following American Railcar (a href="http://finance.yahoo.com/q?s=ARII"ARII/a) for awhile now. It likely showed up on some screen I ran for companies sitting on lots of cash. And cash they have. $13.74/share in cash (the stock trades around $7.40 today). Typical deep value play; half of book value etc. They are also sitting on $275M in debt and a business that is hurting in a difficult economy, but there is some value here. Apparently Carl Icahn also thinks so. He's held shares in American Railcar for a couple of years, but recently raised his stake by a lot in the last quarter (he now owns 54% of the company). It appears he's looking to a href="http://finance.yahoo.com/news/Icahn-company-setting-up-apf-15506456.html?.v=5"take some action as well/a.br /br /ulliStockholders of American Railcar Industries Inc., a St. Charles, Mo.-based company, voted on Wednesday to change the company's incorporation from Delaware to ...

For Immediate Release

Chicago, IL - May 6, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Corporate Executive Board (EXBD), Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly (LLY), Alkermes (ALKS) and Pfizer Inc. (PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Tuesday's Analyst Blog:

Corp. Exec Board Retains Sell Rec

We reiterate our Sell rating on shares of The Corporate Executive Board (EXBD) after the company lowered its full-year outlook in conjunction with its first-quarter earnings release.

The quarterly results were actually above our expectation

...